|
||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||
|
Sana Biotechnology
|
2019 | |||
Sana Biotechnology Q2 2022 |
Sana Biotechnology Q3 2022 |
Sana Biotechnology Q4 2022 |
|
Aug. 4, 2022 | Nov. 2, 2022 | March 16, 2023 |
Sana Biotechnology (SANA) is a preclinical-stage biotechnology company specializing in cell therapies for blood cancers.
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
ILMN |
IMGN |
INCY |
INKT |
INO |
IONS |
MCHP |
MRNA |
PLX |
RETA |
REGN |
RNA |
SAGE |
SGEN |
SYRS |
VSTM |
VRTX |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers